DrugPatentWatch Database Preview
« Back to Dashboard
The generic ingredient in EDURANT is rilpivirine hydrochloride. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the rilpivirine hydrochloride profile page.
Generic Entry Opportunity Date for 202022
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 202022
|Mechanism of Action||Non-Nucleoside Reverse Transcriptase Inhibitors |
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||TABLET;ORAL||Strength||EQ 25MG BASE|
|Approval Date:||May 20, 2011||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Feb 1, 2021|
|Regulatory Exclusivity Use:||INFORMATION ADDED TO SECTION 8.1 OF THE LABELING REGARDING PREGNANT PATIENTS WHO ARE ALREADY ON A STABLE RILPIVIRINE REGIMEN PRIOR TO PREGNANCY AND WHO ARE VIROLOGICALLY SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES/ML)|
|Patent:||➤ Try a Free Trial||Patent Expiration:||Feb 26, 2021||Product Flag?||Y||Substance Flag?||Y||Delist Request?|
|Patent:||➤ Try a Free Trial||Patent Expiration:||Dec 20, 2019||Product Flag?||Y||Substance Flag?||Y||Delist Request?|
Complete Access Available with Subscription